A research group from the Imperial College London claimed a drug called MVT-602 found out recently can be used to target a hormone called kisspeptin and treat reproductive issues in women.Reproductive health issues leading infertility, is one of the major cause of distress. Multiple treatments are available to treat fertility issues and IVF are available to help couples conceive, experts believe still much more needed to be done to find more effective ways to treat infertility and reproductive health issues. 

Kisspeptin is a hormone secreted inside the hypothalamus region of the brain, stimulates the pituitary gland to release neurotransmitters inturn stimulates the release of two reproductive hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH), important role in production of oestrogen and testosterone. Low or inadequate levels of kisspeptin prevents menstruation, cause infertility and also delay or prevent puberty onset. Kisspeptin injections are used to trigger ovulation and help with in-vitro insemination. However, the effects of the hormone only last for a few hours. 

MVT-602 is an oligopeptide (short chain of amino acids) that acts as an agonist of kisspeptin. The researchers involved 12 healthy women, six women with polycystic ovary syndrome (PCOS) and six with hypothalamic amenorrhea women groups. The reproductive hormone levels of women after receiving MVT-602 and natural kisspeptin and the difference in reproductive hormone levels has been compared between the groups. The drug leads to an increase in reproductive hormone levels, LH levels were found in peak for about two days, LH increase is same for  healthy women and women with PCOS. 

First Americans Could Get COVID-19 Vaccine by Mid-Dec: Health experts

Mammoth operation: Shipping 2 bn doses of COVID-19 vaccines: UNICEF

Sputnik V to be priced lesser than Moderna and Pfizer vaccines